

Editor-in-Chief:

S.J. Enna University of Kansas, USA

Editors:

J.G. Piette
G.Z. Feuerstein
M. Williams

University of Liège, Belgium
Farmacon, LLC, USA
Northwestern University, USA

Biochemical Pharmacology Editorial Office:

University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 4016, Kansas City,
Kansas 66160, USA, Tel: +1-913-588-7533, Fax: +1-913-588-7373, Email: BP@kumc.edu

EDITORIAL ADVISORY BOARD:

Antibiotics & Chemotherapeutics

B.B. Aggarwal University of Texas M.D. Anderson Cancer Center, USA
C. Bailly Institut de Recherche Pierre Fabre, France
S. Ceruti University of Milano, Italy
B.S. Cummings University of Georgia, USA
M. Davies M D Anderson Cancer Center, USA
E. De Clercq Catholic University of Leuven, Belgium
M. Diederich Cancer and Blood Disease Research Foundation, Luxembourg
J.D. Docquier University of Siena, Italy
C. Elferink University of Texas Medical Branch, USA
M. Galleni University of Liège, Belgium
H.P. Gerber Pfizer Biotherapeutics, USA
O. Handa Kyoto Prefectural University of Medicine, Japan
F.A.E. Kruyt University Medical Center Groningen, The Netherlands
C. Michiels University of Namur, Belgium
J. Neyts KULeuven - University of Leuven, Belgium
B.A. Ruggeri Cephalon, Inc., USA
G.L. Russo National Research Council, Italy
S. S. Singhal University of North Texas Health Science Center, USA
K. Smalley Moffitt Cancer Center, USA
B.A. Teicher NIH National Cancer Institute, USA
K.D. Tew Medical University of South Carolina, USA
J. Wang Shanghai Medicilon, Inc., P.R. China
F. Zunino National Institute for the Study and Cure of Tumors, Italy

Cardiovascular

M.R. Bennett University of Cambridge, UK
Y.-H. Feng Uniformed Services University of the Health Sciences, USA
B. M. Frey-von Matt University of Bern, Switzerland
R.A. Khalil Harvard Medical School, USA
D. Miller Wyeth Research, USA
K. Mullane San Jose CA, USA
D. Newby University of Edinburgh, UK
E.H. Ohlstein Venuvics Pharmaceuticals, USA
R.G. Schaub Archemix Corporation, USA
A.M. Schmidt Columbia University Medical Center, New York, USA
B. Staels University of Lille II, France
J. Winaver Technion, IIT, Israel
R.J. Winquist Vertex Pharmaceuticals, USA

Metabolic Disorders and Endocrinology

N. Chattopadhyay Central Drug Research Institute, India
A. Kowluru Wayne State University, USA
J. Pierre INSERM U93-01, France
M.E. Poirot INSERM U563, France
C.D. Sutherland University of Dundee, UK

Inflammation & Immunopharmacology

M.J. Alcaraz University of Valencia, Spain
R. Beyaert University of Gent, Belgium
A. Bowie Trinity College, Ireland
M. Burczynski F. Hoffmann-La Roche Ltd., USA
F. D'Acquisto William Harvey Research Institute, UK
J. El Benna Université Paris (INSERM), France
M.P. Fink Veterans Administration of Greater Los Angeles, USA
K.B. Glaser Abbott Laboratories, USA
J.-H. Lai National Defense Medical Center, Taiwan, ROC
O. Léo Université Libre de Bruxelles, Belgium
A. Miller Carmel Medical Center, Israel
J.J. Moreno University of Barcelona, Spain
M. Mousli University of Strasbourg, France
D. R. Webb Celgene Research, USA

Neuropharmacology

D.C. Bertrand University of Geneva, Switzerland
R.A.J. Challiss University of Leicester, UK
C. Forray Lundbeck Research USA
M.F. Jarvis Abbott Laboratories, USA
M.J. Kuhar Emory University, USA
R. Lewis University of Queensland, Australia
M.J. Marino Merck & Co., Inc., USA
P. McGonigle PsychoGenics, USA
H. Möhler University of Zurich, Federal Institute of Technology, Switzerland
R.D. Spealman Harvard University Medical School, USA
D.J. Triggle State University of New York - Buffalo, USA
D. Weinschenker Emory University, USA
J.M. Witkin Lilly Corporate Center, USA

Pharmacokinetics & Drug Metabolism

Kyoto Pharmaceutical University, Japan

Toxicology

K.W. Bock University of Tübingen, Germany
B.J. Day National Jewish Medical and Research Center, USA